Deloitte at the DIA 2017 annual meeting

Chicago, IL | June 18-22, 2017

Look again at the journey of care. Better evidence. Better collaboration. Better patients.

Translate better evidence into better results

Deloitte is bringing together leaders across the Life Sciences and Federal Health practices as well as from ConvergeHEALTH by Deloitte at this year's Drug Information Association (DIA) 2017 annual meeting. Amid pricing pressures, regulatory changes, clinical and operational innovation, consumer engagement, and evolving technology advancements, growth opportunities exist for life sciences companies. To mark an effective response to these changes, life sciences organizations are considering the growing body of health care evidence to break down functional silos and facilitate industry collaboration to identify targeted breakthrough innovations, rapidly get the new products through development, and successfully launch and market them in a value-driven targeted environment.

Date and time

June 18-22, 2017


Chicago, IL

Join us in booth #840 as we discuss the evolving health care ecosystem and the trends impacting life sciences companies.

Deloitte's helps solve your most pressing issues. Join our demos at booth #840.

R&D connect for Life Sciences
R&D connect is a digital, cloud–based suite of clinical apps supporting clinical trial execution and monitoring, mobile innovation, and collaboration and project management. This industry offering provides Life Sciences Research and Development organizations the ability to transform their business operations in an ever-changing healthcare landscape. 

ConvergeHEALTH safetyTM
Optimizing patient outcomes requires a shift from the traditional transactional and risk–based safety approach, to an end–to–end integrated and evidence–based model for safety intelligence. ConvergeHEALTH safetyTM is the first purpose–built integrated platform developed expressly to enable the evidence–based approach. ConvergeHEALTH safetyTM provides capabilities across the pharmacovigilance (PV) lifecycle enabled modular components that can be deployed based on individual client needs.

Identification of Medicinal Products (IDMP) accelerators
IDMP is a set of five data standards from ISO that allow for the definition, characterization, and unique identification of regulated pharmaceutical products across their lifecycle, from early clinical development through marketing authorization, ongoing management, changes, and ultimately withdrawal. Find out about Deloitte's accelerators that help biopharma companies to speed up their analysis of current state readiness for IDMP and to more efficiently capture and maintain their data to achieve compliance.

Deloitte sessions

Monday, June 19 | 2:00 pm–2:30 pm

21st Century Cures Act: Laying the Ground Work for Innovation

Innovation theater session

Wednesday, June 21 | 10:30 am–11:45 am

The Brave New World: The Ongoing Globalization of Pharmacovigilance

Speakers: Glenn Carroll; Jeffrey Ho; Sandra van der Poel; Mirza Rahman

Wednesday, June 21 | 2:00 pm–3:15 pm

Pharmacovigilance 2.0: Redesigning for the Future

Speakers: Annette S. Williams, MBA, RPh; John Whitebrook, PhD; Sundeep Surendra Sethi, MD, MBA; Robert A. Taylor


Stop by for coffee

Energize your experience on the DIA conference floor and beyond
  • Stop by for coffee and happy hour
  • Stop by booth #840 and grab a cup of coffee on the exhibit floor Monday, Tuesday, and Wednesday from 9 a.m. to noon

Don't miss DIA news as it happens

Follow @DeloitteHealth, @DeloitteProduct, and @Deloittegov on Twitter to stay tuned in to the latest news and trends from the DIA 2017 conference and insights from Deloitte life sciences leaders.